Home Cart Sign in  
Chemical Structure| 790702-57-7 Chemical Structure| 790702-57-7

Structure of NGI-1
CAS No.: 790702-57-7

Chemical Structure| 790702-57-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML414 (NGI-1) is an inhibitor of oligosaccharyltransferase (OST) with IC50 of 1.1 µM by targeting catalytic subunits STT3A and STT3B.

Synonyms: ML414; N-linked Glycosylation Inhibitor 1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NGI-1

CAS No. :790702-57-7
Formula : C17H22N4O3S2
M.W : 394.51
SMILES Code : O=C(NC1=NC=C(C)S1)C2=CC(S(=O)(N(C)C)=O)=CC=C2N3CCCC3
Synonyms :
ML414; N-linked Glycosylation Inhibitor 1
MDL No. :MFCD06358908
InChI Key :QPKGRLIYJGBKJL-UHFFFAOYSA-N
Pubchem ID :2519269

Safety of NGI-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H1975-OR 10μM 5 days NGI-1 reduced proliferation of H1975-OR cells by ~70% and caused G1 cell cycle arrest. PMC6125176
HCC827-GR 10μM 5 days NGI-1 reduced proliferation of HCC827-GR cells by ~80% and caused G1 cell cycle arrest. PMC6125176
PC9-GR2 10μM 5 days NGI-1 reduced proliferation of PC9-GR2 cells by ~90% and caused G1 cell cycle arrest. PMC6125176
PC9-GR1 10μM 5 days NGI-1 reduced proliferation of PC9-GR1 cells by ~90% and caused G1 cell cycle arrest. PMC6125176
Huh7 cells 8 μM 48 hours NGI-1 significantly reduced DENV and ZIKV infectivity PMC5734657
T98G 10 μM 48 hours NGI-1 reduced phosphorylation of PDGFR but had no significant effect on radiosensitivity in T98G cells. PMC6314911
U251 10 μM 48 hours NGI-1 reduced phosphorylation of MET but had no significant effect on radiosensitivity in U251 cells. PMC6314911
SKMG3 10 μM 48 hours NGI-1 reduced protein levels of ErbB2 and ErbB3, and enhanced radiosensitivity in SKMG3 cells. PMC6314911
D54 10 μM 48 hours NGI-1 reduced glycosylation and phosphorylation of EGFR, ErbB2, and ErbB3, and enhanced radiosensitivity in D54 cells. PMC6314911
HN4 cells 0-20 μmol/L 24 hours Inhibited STT3B-mediated glycosylation of EREG, leading to its degradation and suppression of PDL1 PMC11214941
HEK293T-ACE2 cells 1 μM 48 hours To evaluate the effect of NGI-1 on SARS-CoV-2 and its variant pseudovirus infectivity, results showed that NGI-1 significantly reduced pseudovirus infectivity. PMC8613501
Vero E6 cells 1.863 μM 1 hour pretreatment To evaluate the effect of NGI-1 on SARS-CoV-2 infectivity, results showed that NGI-1 significantly reduced viral protein expression and infectivity. PMC8613501
HEK293T cells 10 μM 24 hours To evaluate the effect of NGI-1 on SARS-CoV-2 spike protein glycosylation, results showed that NGI-1 treatment reduced the molecular weight of spike protein, indicating glycosylation inhibition. PMC8613501
HEK293 cells 1 μM and higher 48 hours NGI-1 significantly inhibited DENV and ZIKV replication with EC50 values of 0.85 μM and 2.2 μM, respectively PMC5734657
Madin-Darby canine kidney (MDCK) epithelial cells 10.0 μM 1 hour to 24 hours To evaluate the effect of NGI-1 on influenza virus growth, results showed that NGI-1 treatment significantly reduced the infectious titers of influenza viruses PMC9040841
Normal human bronchial epithelial (NHBE) cells 10.0 μM 1 hour to 24 hours To evaluate the effect of NGI-1 on influenza virus growth, results showed that NGI-1 treatment significantly reduced the infectious titers of all tested influenza viruses PMC9040841
MCF7 breast carcinoma cells 10 µM 48 hours To evaluate the inhibitory effect of NGI-1 on protein glycosylation and its impact on entosis. Results showed that NGI-1 significantly increased the number of entotic structures and increased the proportion of apoptotic+necrotic cells after ROCKi treatment. PMC9402552
293T cells 10 μM 24 hours Inhibited glycosylation of LAMP1 and LAMP2A, similar to the effects observed with ALKBH1 overexpression PMC10933178
HeLa cells 10 μM 24 hours Inhibited glycosylation of LAMP1 and LAMP2A, similar to the effects observed with ALKBH1 overexpression PMC10933178

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female athymic Swiss nu/nu mice HCC827-GR and H1975-OR xenografts Intravenous injection 20 mg/kg Three times per week for a total of 8 doses NGI-1 nanoparticles significantly delayed the growth of HCC827-GR and H1975-OR xenografts, with enhanced effects when combined with EGFR TKIs. PMC6125176
Nude mice D54 and SKMG3 xenograft models Intravenous injection 20 mg/kg Every other day for a total of 3 doses NGI-1 NPs significantly inhibited the growth of D54 and SKMG3 xenografts and showed better efficacy when combined with radiotherapy. PMC6314911
C57BL/6 mice MTCQ1 syngeneic model Intraperitoneal injection 10 mg/kg 4 times per week, during treatment Combination of NGI-1 with anti-PDL1 therapy significantly enhanced immunotherapy efficacy PMC11214941
BALB/c nude mice Xenograft tumor model Intraperitoneal injection 20 mg/kg 3 times per week for a total of 8 doses NGI-1 significantly inhibited the growth of PC-9 xenograft tumors, reducing tumor volume and wet weight PMC9271429

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.67mL

2.53mL

1.27mL

25.35mL

5.07mL

2.53mL

References

 

Historical Records

Categories